| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
113,340,000 |
| Market
Cap: |
108.83(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6758 - $2.34 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
| Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
924,350 |
1,173,939 |
1,216,699 |
1,560,865 |
| Total Sell Value |
$901,474 |
$1,198,663 |
$1,255,793 |
$3,019,031 |
| Total People Sold |
4 |
7 |
7 |
8 |
| Total Sell Transactions |
8 |
26 |
36 |
61 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shacham Sharon |
President & CSO |
• – – |
2020-02-19 |
4 |
S |
$16.48 |
$145,321 |
I/I |
(8,817) |
555,122 |
|
-10% |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-02-19 |
4 |
S |
$16.48 |
$145,321 |
D/D |
(8,817) |
756,489 |
|
-10% |
|
| Primiano Christopher Brett |
EVP, CBO, GC & Secretary |
• – – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,675 |
13,328 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
21,800 |
765,306 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,800 |
563,939 |
|
- |
|
| Shah Jatin |
EVP, Chief Medical Officer |
• – – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,850 |
42,134 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
21,800 |
563,939 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,800 |
765,306 |
|
- |
|
| Frenkel Ran |
Chief Dev Operations Officer |
• – – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,675 |
39,041 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-02-11 |
4 |
AS |
$17.43 |
$174,294 |
D/D |
(10,000) |
542,139 |
|
10% |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-02-11 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
552,139 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-02-11 |
4 |
AS |
$17.43 |
$174,294 |
I/I |
(10,000) |
542,139 |
|
10% |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-02-11 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
552,139 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-02-10 |
4 |
AS |
$16.93 |
$169,327 |
I/I |
(10,000) |
743,506 |
|
10% |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-02-10 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
753,506 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-02-10 |
4 |
AS |
$16.93 |
$169,327 |
D/D |
(10,000) |
743,506 |
|
10% |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-02-10 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
753,506 |
|
- |
|
| Mirza Mansoor Raza |
Director |
– • – |
2020-01-09 |
4 |
AS |
$20.00 |
$41,120 |
D/D |
(2,056) |
0 |
|
0% |
|
| Mirza Mansoor Raza |
Director |
– • – |
2020-01-09 |
4 |
OE |
$8.06 |
$16,571 |
D/D |
2,056 |
2,056 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-01-09 |
4 |
AS |
$19.19 |
$191,880 |
D/D |
(10,000) |
542,139 |
|
0% |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-01-09 |
4 |
OE |
$4.75 |
$47,520 |
D/D |
10,000 |
552,139 |
|
- |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-01-09 |
4 |
AS |
$19.19 |
$191,880 |
I/I |
(10,000) |
542,139 |
|
0% |
|
| Shacham Sharon |
President & CSO |
• – – |
2020-01-09 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
552,139 |
|
- |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-01-08 |
4 |
AS |
$18.57 |
$185,705 |
I/I |
(10,000) |
743,506 |
|
0% |
|
| Kauffman Michael |
Chief Executive Officer |
• • – |
2020-01-08 |
4 |
OE |
$4.75 |
$47,520 |
I/I |
10,000 |
753,506 |
|
- |
|
592 Records found
|
|
Page 11 of 24 |
|
|
0.01 (1.31%) 
